Published in Heart on June 28, 2006
Behaviour change techniques in home-based cardiac rehabilitation: a systematic review. Br J Gen Pract (2016) 0.75
Cardiac rehabilitation improves the blood plasma properties of cardiac patients. Exp Biol Med (Maywood) (2016) 0.75
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet (1986) 6.51
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 6.13
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 5.87
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 5.53
Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol (1995) 5.26
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med (2000) 4.43
Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol (2004) 3.48
Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation (2004) 3.02
Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med (1990) 2.79
Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation (1991) 2.62
The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57
Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol (2000) 1.95
Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol (1997) 1.72
Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis (1997) 1.57
Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J (1996) 1.53
Medically directed at-home rehabilitation soon after clinically uncomplicated acute myocardial infarction: a new model for patient care. Am J Cardiol (1985) 1.53
Cardiac rehabilitation services in England and Wales: a national survey. Int J Cardiol (1997) 1.48
Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: pooled analysis of diverse patient populations. Am J Physiol Heart Circ Physiol (2003) 1.38
Program participation, exercise adherence, cardiovascular outcomes, and program cost of traditional versus modified cardiac rehabilitation. Am J Cardiol (2000) 1.35
Effect of exercise on upper and lower extremity endothelial function in patients with coronary artery disease. Am J Cardiol (2002) 1.28
Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev (2000) 1.28
Exercise training in coronary artery disease and coronary vasomotion. Circulation (2001) 1.21
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol (1997) 1.17
Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med (2003) 1.16
Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol (1999) 1.08
Effect of exercise training on endothelial function in men with coronary artery disease. Am J Cardiol (2004) 1.07
Alternatives for cardiac rehabilitation patients unable to return to a hospital-based program. Heart Lung (1993) 1.07
Exercise training improves conduit vessel function in patients with coronary artery disease. J Appl Physiol (1985) (2003) 1.06
Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. BMC Cardiovasc Disord (2003) 1.04
High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: Relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens (2005) 1.04
Impact of physical training and detraining on endothelium-dependent vasodilation in patients with recent acute myocardial infarction. Am Heart J (2004) 1.02
The effect of exercise training on endothelial function in cardiovascular disease in humans. Exerc Sport Sci Rev (2004) 1.01
Outpatient cardiac rehabilitation: are the potential benefits being realised? J R Coll Physicians Lond (1997) 0.94
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol (2001) 0.91
Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens (2000) 0.91
Influence of power and aerobic exercise training on haemostatic factors after coronary artery surgery. Br Heart J (1992) 0.89
Benefits of cardiac rehabilitation and exercise training. Chest (2000) 0.87
Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol (1997) 0.87
Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. Am Heart J (2002) 0.86
Blood coagulability and fibrinolytic activity before and after physical training during the recovery phase of acute myocardial infarction. Clin Cardiol (1992) 0.86
Cardiac rehabilitation in Scotland: is current provision satisfactory? J Public Health Med (1996) 0.83
Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study. Thromb Haemost (2001) 0.83
Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J (1995) 0.80
Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am (2001) 0.78
Association between plasma viscosity and all-cause mortality: results from the MONICA-Augsburg Cohort Study 1984-92. Br J Haematol (2000) 0.76
Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ (2012) 5.28
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Fibrinogen: biochemistry, epidemiology and determinants. QJM (2003) 2.05
Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens (2005) 2.05
The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart (2008) 2.03
Platelet activation: assessment and quantification. Eur Heart J (2001) 2.02
Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J Intern Med (2014) 1.86
Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM (2007) 1.76
A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost (2011) 1.62
Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol (1999) 1.62
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J (2001) 1.60
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol (2012) 1.60
High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost (2012) 1.55
A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol (2000) 1.54
Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med (2007) 1.53
Increased 5-year mortality in the migrant South Asian stroke patients with diabetes mellitus in the United Kingdom: the West Birmingham Stroke Project. Int J Clin Pract (2007) 1.50
Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost (2006) 1.49
Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. J Hum Hypertens (2012) 1.49
Systemic responses in patients with intermittent claudication after treadmill exercise. Br J Surg (1994) 1.48
Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost (2006) 1.45
Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia (2006) 1.41
Should oral glucose tolerance testing be mandatory following acute myocardial infarction? Int J Clin Pract (2007) 1.41
Obstructive sleep apnoea and metabolic syndrome: two sides of the same coin? J Hum Hypertens (2008) 1.39
The acute influence of smoking on the endothelium. Atherosclerosis (1992) 1.39
A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. J Intern Med (2000) 1.38
Interventions to reduce or prevent obesity in pregnant women: a systematic review. Health Technol Assess (2012) 1.33
Galactofuranoic-oligomannose N-linked glycans of alpha-galactosidase A from Aspergillus niger. Eur J Biochem (2001) 1.32
Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost (2010) 1.32
Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology (2001) 1.31
Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost (2011) 1.31
Death rate from asthma. BMJ (1993) 1.26
Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens (2007) 1.23
Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br J Biomed Sci (2000) 1.23
Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost (2011) 1.23
Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest (2003) 1.19
Peripheral vascular disease and Virchow's triad for thrombogenesis. QJM (2002) 1.19
Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci (2000) 1.18
Public health benefits of weight loss: in response to Dixon et al. J Public Health (Oxf) (2013) 1.16
Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol (2001) 1.15
Rate control in the medical management of atrial fibrillation. Heart (2006) 1.13
Ethnic differences in blood pressure and the prevalence of hypertension in England. J Hum Hypertens (2002) 1.12
The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost (2012) 1.11
The potential impact of periodontal disease on general health: a consensus view. Curr Med Res Opin (2008) 1.09
Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol (2004) 1.07
Left atrial thrombin generation and prothrombin fragment 1+2. Clin Sci (Lond) (2000) 1.07
Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis (2002) 1.06
Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart (2003) 1.06
Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM (2003) 1.02
Circulating endothelial cells: markers of vascular dysfunction. Clin Lab (2005) 1.00
Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost (2013) 1.00
Biomarkers in atrial fibrillation: an overview. Int J Clin Pract (2013) 0.99
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer (2011) 0.99
Transferrin receptor bearing cells in the peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol (1985) 0.99
Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation (2001) 0.99
Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke (2000) 0.99
Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst (2000) 0.98
Lone atrial fibrillation - an overview. Int J Clin Pract (2013) 0.98
Is exercise associated with primary dysmenorrhoea in young women? BJOG (2010) 0.97
An investigation into the acute vascular effects of riveting. Br J Ind Med (1993) 0.97
The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM (2003) 0.96
Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J (2000) 0.96
Quality of life in adults with congenital heart disease. Heart (2002) 0.95
Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. J Thromb Haemost (2013) 0.95
Cell hybrids: an important new source of antibody production. Med Lab Sci (1979) 0.94
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess (2000) 0.94
National service framework for coronary heart disease. Many operators and facilities will not meet standards set out in framework. BMJ (2000) 0.94
Systolic vs diastolic blood pressure and the burden of hypertension. J Hum Hypertens (2002) 0.94
Plasma, platelet and erythrocyte glutathione peroxidases as risk factors in ischaemic heart disease in man. Clin Sci (Lond) (1992) 0.94
Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension. Eur J Clin Invest (2005) 0.94
Lone atrial fibrillation: what is known and what is to come. Int J Clin Pract (2011) 0.94
Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. Int J Cardiol (2003) 0.93
Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med (2005) 0.93
Platelets and atrial fibrillation. Eur Heart J (2001) 0.93
Compliance with pharmacological therapy in hypertension: can we do better, and how? J Hum Hypertens (2004) 0.92
Collateralization and the response to obstruction of epicardial coronary arteries. QJM (2004) 0.92
Cell adhesion molecules in cardiovascular disease and its risk factors--what can soluble levels tell us? J Clin Endocrinol Metab (2000) 0.92
The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie (2008) 0.92
von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J Rheumatol (1993) 0.91
Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract (2005) 0.91
von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J (1995) 0.91
Blood pressure control in the setting of diabetes mellitus: new targets, new hope for improvement? J Hum Hypertens (2006) 0.91
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest (2003) 0.91
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J (2013) 0.91
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart (2004) 0.91
Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost (1994) 0.91
Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond) (1998) 0.90
Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens (1995) 0.90
Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation (2000) 0.90
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ (2011) 0.90
White blood cell count and hypertension. J Hum Hypertens (2006) 0.90
Vascular responses in chain saw operators. Occup Environ Med (1994) 0.90
Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function. J Intern Med (2008) 0.90